Actively Recruiting
CRYSTALSIGHT Cohort 2.0
Led by Tan Tock Seng Hospital · Updated on 2026-01-08
60
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate OCCUTRACK's CRYSTALSIGHT device through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.
CONDITIONS
Official Title
CRYSTALSIGHT Cohort 2.0
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 55 and 99 years old
- Any gender
- Able to understand spoken instructions in British/American English, Chinese, or Bahasa Melayu
- Able to operate and connect the CRYSTALSIGHT device to a computer independently or with family help
- Currently treated for wet age-related macular degeneration without symptoms of active disease recurrence
- Able to follow the study protocol as judged by the investigator
- Able to provide informed consent and sign consent form before assessments
You will not qualify if you...
- Unable to understand spoken instructions or demonstrate device use
- Unable to connect and turn on the CRYSTALSIGHT device independently
- Had any eye surgery within the last 3 months or vitrectomy within the last 12 months
- Any macular disease unrelated to AMD affecting vision or causing retinal fluid
- Any other eye condition that may reduce visual improvement or need treatment during the study
- Prior or current treatment for choroidal neovascularization or vitreomacular-interface problems in the study eye
- History of idiopathic or autoimmune uveitis in either eye
- Active eye inflammation or infection in either eye
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tan Tock Seng Hospital
Singapore, Singapore, 308433
Actively Recruiting
Research Team
Z
Zheng Kuang, Noel Soh, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here